P62: An emerging oncotarget for osteolytic metastasis

Area of Science:

• Oncology
• Cell Biology
• Bone Biology

Background:

• Bone metastasis is a common complication of advanced cancers, leading to poor prognosis.
• Osteolytic metastasis involves a detrimental cycle between tumor cells and bone cells, particularly osteoclasts.
• The P62 adapter protein is implicated in both tumor progression and metastasis, and influences osteoclast formation.

Purpose of the Study:

• To review the multifaceted roles of P62 in tumor cells and osteoclasts.
• To elucidate the P62-related signaling pathways in osteolytic bone metastasis.
• To discuss P62 as a potential therapeutic target for osteolytic bone metastasis.

Main Methods:

• Literature review focusing on P62's function in tumorigenesis, metastasis, and osteoclastogenesis.
• Analysis of P62's role in the "vicious cycle" of osteolytic metastasis.
• Examination of recent findings on P62-targeted therapies, including DNA vaccines.

Main Results:

• P62 overexpression is linked to increased tumorigenesis and metastasis.
• P62 significantly modulates osteoclastogenesis, contributing to the osteolytic bone microenvironment.
• P62 DNA vaccines have demonstrated anti-tumor, anti-metastatic, and anti-osteoporotic effects.

Conclusions:

• P62 is a critical mediator in the pathogenesis of osteolytic bone metastasis.
• Targeting P62 presents a promising therapeutic strategy for osteolytic bone metastasis.
• Further research into P62-based treatments could offer new hope for patients with bone metastasis.